Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3489-3505

  Duan, Jinghua ^a,b   Vogt, Frederick G ^c   Li, Xiaojian ^a   Hayes, Don ^d,e   Mansour, Heidi M ^f  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GLAXOSMITHKLINE   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aerosol; Fluoroquinolone antibiotic drug delivery; Lung infection; Lung surfactant; Respiratory; Solid state particle engineering design

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; LUNG SURFACTANT; MOXIFLOXACIN; NANOCRYSTAL; NANOPARTICLE; OFLOXACIN;

AEROSOL; ARTICLE; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CONTROLLED STUDY; DISPERSION; DRUG DESIGN; DRUG STRUCTURE; DRY POWDER; DRY POWDER INHALER; INFRARED SPECTROSCOPY; INHALATIONAL DRUG ADMINISTRATION; MICROPARTICLE; NANOMEDICINE; PARTICLE SIZE; RAMAN SPECTROMETRY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SPRAY DRYING;

AEROSOL; FLUOROQUINOLONE ANTIBIOTIC DRUG DELIVERY; LUNG INFECTION; LUNG SURFACTANT; RESPIRATORY; SOLID-STATE PARTICLE ENGINEERING DESIGN;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DESICCATION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; GASES; NANOPARTICLES; OFLOXACIN; PARTICLE SIZE; POWDERS; QUINOLINES; SOLUTIONS;

EID: 84884553984     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S48631     Document Type: Article

References (50)

1. Todd PA, Faulds D. Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs. 1991;42(5):825-876.
2. Ludwig E. Controversies on pharmacokinetics of fluoroquinolones in elderly patients. Int J Antimicrob Agents. 1993;3(1):49-59.
3. Humma LM. Prevention and treatment of drug-resistant tuberculosis. Am J Health Syst Pharm. 1996;53(19):2291-2298; quiz 2335.
4. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis. 1997;25(5): 1213-1221.
5. Kawahara S, Tada A, Nagare H. Clinical evaluation of new quinolones as antituberculosis drugs. Kekkaku. 1999;74(1):71-75.
6. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003;168(11):1342-1345.
7. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299-319.
8. Song JH. What's new on the antimicrobial horizon? Int J Antimicrob Agents. 2008;32 Suppl 4:S207-S213.
9. Garcia-Contreras L, Hickey AJ. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv Drug Deliv Rev. 2002;54(11): 1491-1504.
10. Mansour HM, Rhee YS, Park CW, DeLuca PP. Lipid nanoparticulate drug delivery and nanomedicine. In: Moghis A, editor. Lipids in Nano-technology. 1st ed. Urbana, IL: American Oil Chemists Society (AOCS) Press; 2011:221-268.
11. Hayes D Jr, Murphy BS, Mullett TW, Feola DJ. Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology. 2010;15(1):184-186.
12. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol. 2006;533(1-3):341-350.
13. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv. 2010;7(7):781-794.
14. Park CW, Hayes DJr, Mansour HM. Pulmonary inhalation aerosols for targeted antibiotics drug delivery. European Pharmaceutical Review. 2011;16(1):32-36.
15. Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med. 1996;9(1):111-122.
16. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother. 2009;53(9):3847-3854.
17. Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv. 2009;22(2):131-138.
18. Willis L, Hayes D Jr, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190(3): 251-262.
19. Ventura CA, Tommasini S, Crupi E, et al. Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies. Eur J Pharm Biopharm. 2008;68(2):235-244.
20. Park JH, Jin HE, Kim DD, Chung SJ, Shim WS, Shim CK. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm. 2013;441(1-2):562-569.
21. Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release. 2008;129(2):100-106.
22. Palazzo F, Giovagnoli S, Schoubben A, Blasi P, Rossi C, Ricci M. Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. Int J Pharm. 2013;440(2):273-282.
23. Chimote G, Banerjee R. Evaluation of antitubercular drug-loaded sur-factants as inhalable drug-delivery systems for pulmonary tuberculosis. J Biomed Mater Res A. 2009;89(2):281-292.
24. Ganguly S, Moolchandani V, Roche JA, et al. Phospholipid-induced in vivo particle migration to enhance pulmonary deposition. J Aerosol Med Pulm Drug Deliv. 2008;21(4):343-350.
25. Mansour H, Wang DS, Chen CS, Zografi G. Comparison of bilayer and monolayer properties and phospholipid systems containing dipalmitoylphosphatidyglycerol and dipalmitoylphosphatidylinositol. Langmuir. 2001;17(21):6622-6632.
26. Mansour HM, Zografi G. Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface. Langmuir. 2007;23(7):3809-3819.
27. Mansour HM, Zografi G. The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. J Pharm Sci. 2007;96(2):377-396.
28. Hickey AJ, Mansour HM. Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. In: Rathbone MJ, editor. Modified-Release Drug Delivery Technology. New York, NY: Informa Healthcare; 2008:573-602.
29. Hickey AJ, Mansour HM. Delivery of drugs by the pulmonary route. In: Florence AT, Siepmann J, editors. Modern Pharmaceutics. New York, NY: Taylor and Francis; 2009:191-219.
30. Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci. 2007;96(5):1282-1301.
31. Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci. 2007;96(5):1302-1319.
32. Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care. 2000;45(6):652-666.
33. Wu X, Li X, Mansour HM. Surface analytical techniques in solid-state particle characterization: implications for predicting performance in dry powder inhalers. KONA Powder and Particle Journal. 2010;28:3-19.
34. Xu Z, Mansour HM, Hickey AJ. Particle interactions in dry powder inhaler unit processes. Journal of Adhesion Science and Technology: Special Issue on Adhesion Aspects in Pharmaceutical Sciences. 2011;25(4-5):451-482.
35. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance. J Pharm Sci. 2010;99(8):3442-3461.
36. Adi H, Traini D, Chan HK, Young PM. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci. 2008;97(7):2780-2788.
37. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder and Particle Journal. 1998;16:7-45.
38. Zeng XM, Martin GP, Marriott C. Particulate Interactions in Dry Powder Formulation for Inhalation (Pharmaceutical Science Series). London, UK: Taylor and Francis; 2001.
39. Wu X, Zhang W, Hayes DJr, Mansour HM. Physicochemical character-ization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Int J Nanomedicine. 2013;8:1269-1283.
40. Wu X, Hayes DJr, Zwischenberger JB, Kuhn RJ, Mansour HM. Design and physicochemical characterization of advanced spray-dried tacroli-mus multifunctional particles for inhalation. Drug Des Devel Ther. 2013;7:59-72.
41. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphati-dylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine. 2013;8:275-293.
42. Li X, Mansour HM. Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery. AAPS PharmSciTech. 2011;12(4):1420-1430.
43. Li X, Hayes D, Mansour HM. Targeted lung delivery by inhalable multifunctional microparticulate/nanoparticulate aerosols for cystic fibrosis combination drug/mucolytic treatment. Pediatr Pulmonol. 2011;346-346.
44. Park CW, Rhee YS, Vogt FG, et al. Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex vivo in respiratory drug delivery: an invited paper. Adv Drug Deliv Rev. 2012;64(4):344-356.
45. Mansour HM, Hickey AJ. Raman characterization and chemical imaging of biocolloidal self-assemblies, drug delivery systems, and pulmonary inhalation aerosols: a review. AAPS PharmSciTech. 2007;8(4):E99.
46. Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhal-ers monograph. In: USP 29-NF 24: United States Pharmacopoeia and the National Formulary: The Official Compendia of Standards. Vol 29/24. Rockville, MD: United States Pharmacopeial Convention; 2006:2617-2636.
47. Finlay WH. The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction. London, UK: Academic Press; 2001.
48. Finlay W [webpage on the Internet]. ARLA respiratory deposition calculator. Edmonton, AB: Aerosol Research Lab of Alberta; 2008. Available from: http://www.mece.ualberta.ca/arla/impactor_mmad_ calculator.html. Accessed June 20, 2010.
49. Brittain HG. X-ray diffraction III: pharmaceutical applications. Spectroscopy. 2001;16:7.
50. Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technology. 2004;145(2):139-148.